BPH and erectile dysfunction frequently appear in the same man, especially after age 50. Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate that can contribute to lower urinary tract symptoms (LUTS), including a weak stream, urgency, frequency, hesitancy, incomplete emptying, and waking at night to urinate. Erectile dysfunction (ED) is the persistent difficulty achieving or maintaining an erection adequate for sexual activity. These conditions are distinct, but their overlap is too consistent to dismiss as aging alone. They share vascular, smooth-muscle, neurologic, metabolic, and quality-of-life pathways—and some treatments can affect both.
BPH and erectile dysfunction commonly occur together
Neither BPH nor ED is inevitable with age, although both become more common over time. Prostate tissue often grows gradually after midlife. At the same time, hypertension, diabetes, obesity, smoking exposure, medication use, endothelial dysfunction, and declining physical activity can impair erectile physiology. Age therefore acts partly as a marker for accumulated risk rather than a complete explanation.
Recent population data reinforce the association. An analysis of 2,225 US adults from the National Health and Nutrition Examination Survey reported a weighted ED prevalence of 27.47% overall and 47.57% among men identified as having BPH. After adjustment for cardiometabolic and demographic variables, BPH remained independently associated with ED among men aged 60 to 80, with an odds ratio of 1.93.[1] Because this was a cross-sectional analysis, it cannot show that prostate enlargement directly caused ED. It does show that clinicians should ask about both urinary and sexual symptoms rather than treating them as unrelated complaints.
A 2026 systematic review of 11 clinical studies involving 1,254 men with LUTS/BPH found a pooled ED prevalence of 79.53% in hospital- and clinic-based populations.[2] That estimate is much higher than community prevalence and should not be generalized to every man with urinary symptoms; people seeking specialty care tend to have more severe or complex disease. Still, the finding demonstrates how commonly sexual dysfunction accompanies clinically significant LUTS.
Symptom severity also matters. Men bothered by frequent nighttime urination may experience fragmented sleep, fatigue, lower sexual interest, and reduced opportunity for intimacy. Urgency or fear of leakage can create embarrassment. Persistent symptoms may increase anxiety and depressive symptoms, which can further interfere with arousal and erections. The relationship is therefore both biological and behavioral.
Shared biology links prostate symptoms and erections
An erection requires coordinated nerve signaling, relaxation of smooth muscle in the penile arteries and corpora cavernosa, increased arterial inflow, and restriction of venous outflow. Nitric oxide activates cyclic guanosine monophosphate (cGMP), which helps smooth muscle relax. Phosphodiesterase type 5 (PDE5) breaks down cGMP and helps terminate that signal.
Lower urinary tract function also depends on smooth-muscle tone and autonomic nerve activity. PDE5 is expressed in the prostate, bladder, urethra, and associated vasculature. This distribution helps explain why PDE5 inhibition may influence both erectile tissue and urinary symptoms even though it does not substantially shrink the prostate.
Several overlapping mechanisms have been proposed. Reduced nitric oxide signaling may increase smooth-muscle tone in the lower urinary tract while also limiting penile vasodilation. Autonomic overactivity may promote urinary urgency and outlet resistance while making the vascular relaxation required for erection more difficult. Pelvic atherosclerosis and endothelial dysfunction may reduce blood flow to both the bladder/prostate region and the penis. Chronic inflammation, oxidative stress, and metabolic disease may compound these effects.
These mechanisms are plausible, but no single pathway explains every case. A man may have significant prostate enlargement without ED, or ED without urinary symptoms. LUTS can also arise from an overactive bladder, urethral stricture, infection, neurologic disease, medication effects, or prostate cancer. Likewise, ED can be vascular, hormonal, neurologic, medication-related, psychogenic, or mixed. Symptoms require evaluation rather than self-diagnosis.
BPH treatments can affect sexual function differently
Treatment is usually chosen according to symptom burden, prostate size, risk of urinary retention, medical history, and patient priorities. Sexual side effects vary by drug class and procedure.
Alpha-1 blockers such as tamsulosin relax smooth muscle around the prostate and bladder neck. They can improve urine flow relatively quickly but may cause dizziness or low blood pressure. More uroselective agents are particularly associated with ejaculatory dysfunction, including reduced or absent semen during orgasm. That is not identical to ED, although men may experience it as a meaningful change in sexual function.
Five-alpha-reductase inhibitors such as finasteride and dutasteride reduce conversion of testosterone to dihydrotestosterone and can shrink an enlarged prostate over months. Potential adverse effects include reduced libido, ejaculatory changes, and ED in a minority of men. A meta-analysis of randomized trials found more ED with combined alpha-blocker plus five-alpha-reductase-inhibitor therapy than with alpha-blocker therapy alone.[3] These medicines remain clinically useful, particularly for larger prostates and progression risk, but the sexual tradeoffs deserve an explicit discussion.
Procedures range from minimally invasive therapies to transurethral resection and laser-based surgery. Their effects on erections are often smaller than patients fear, but retrograde ejaculation or loss of antegrade ejaculation can be common with some techniques. Outcomes depend on the procedure, baseline function, surgeon experience, and definitions used in studies. Men who value preservation of ejaculation should raise that priority before treatment is selected.
No one should stop a prescribed BPH medicine because of a suspected side effect without speaking with the prescriber. Abruptly changing therapy may worsen urinary symptoms or overlook another cause of sexual dysfunction. A medication review can often identify alternatives, dose adjustments, or a need for further testing.
Daily tadalafil can address two symptom domains
Tadalafil is a PDE5 inhibitor best known for treating ED. In the United States, tadalafil 5 mg once daily is also approved for the signs and symptoms of BPH, including in men who have both BPH and ED. It improves signaling downstream of nitric oxide; it is not a prostate-shrinking drug.
In a randomized, double-blind phase 3 trial, men with both ED and BPH symptoms received tadalafil 2.5 mg, tadalafil 5 mg, or placebo for 12 weeks. Both tadalafil doses significantly improved erectile-function scores compared with placebo, but only the 5 mg dose produced a statistically significant improvement in the International Prostate Symptom Score (IPSS). The mean IPSS change was −6.1 points with tadalafil 5 mg versus −3.8 with placebo.[4]
A systematic review and meta-analysis of 13 randomized trials involving 3,973 participants similarly found that tadalafil 5 mg once daily improved both LUTS and erectile-function measures over 12 weeks compared with placebo.[5] A separate evidence-based analysis found an approximately 1.97-point greater reduction in total IPSS than placebo, with improvements in both storage and voiding subscores.[6] The magnitude is meaningful for some men but not dramatic for everyone, and response varies.
Tadalafil may improve how symptoms feel without producing a large change in maximum urinary flow or residual urine volume. Men with severe obstruction, recurrent urinary retention, kidney effects, bladder stones, repeated infections, or concerning bleeding may need other management. Treatment also requires screening for interactions and contraindications. Tadalafil must not be combined with nitrates because the combination can cause a dangerous fall in blood pressure. Caution is necessary with certain alpha-blockers, substantial cardiovascular disease, and some strong CYP3A4-interacting medicines. Common adverse effects include headache, flushing, indigestion, nasal congestion, back pain, and muscle aches.
Evaluation should cover urinary, sexual, and cardiovascular health
A practical assessment begins with the pattern and duration of symptoms. For LUTS, clinicians may use the IPSS questionnaire, urinalysis, medication review, physical examination, and selectively prostate-specific antigen testing, post-void residual measurement, or urine-flow testing. Fever, painful urination, visible blood in urine, inability to urinate, recurrent infection, or unexplained weight loss warrants prompt medical attention.
For ED, evaluation typically includes cardiovascular risk factors, blood pressure, smoking status, alcohol intake, sleep, mental health, and medications. Depending on the presentation, testing may include fasting glucose or A1c, lipids, and an early-morning testosterone measurement. ED can precede clinically apparent cardiovascular disease because penile arteries are relatively small and may show vascular impairment early.
Lifestyle measures may support both domains. Regular aerobic activity, resistance training, weight management, smoking cessation, moderation of alcohol, and better sleep can improve cardiometabolic health and may support erectile function. Reducing evening fluids, caffeine, and alcohol may lessen nocturia or urgency for some men, but extreme fluid restriction is not appropriate. Constipation management can also reduce pelvic pressure and urinary discomfort.
Tracking both urinary and erectile symptoms before and after a treatment change is useful. A lower IPSS does not automatically mean erections improved, and a better erectile score does not prove bladder obstruction resolved. Separate measures help clinicians see whether a therapy is addressing one problem, both, or neither.
Conclusion
BPH and erectile dysfunction are linked by more than chronology. They frequently coexist, share several physiologic risk pathways, and can influence sleep, confidence, relationships, and quality of life. Treatment should account for urinary severity, sexual priorities, cardiovascular safety, and the possibility that medication itself is contributing. Daily tadalafil has evidence for improving both symptom domains in appropriately selected men, but it does not replace evaluation for obstruction, prostate disease, metabolic risk, or other causes of ED.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. You can also review more evidence-based men's health information in the blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Guo J, et al. A comprehensive analysis of erectile dysfunction prevalence and the impact of prostate conditions on ED among US adults: evidence from NHANES 2001–2004. Frontiers in Endocrinology. 2024;15:1412369. doi:10.3389/fendo.2024.1412369
- Musonda MM, et al. Prevalence of erectile dysfunction in men with lower urinary tract symptoms/benign prostatic hyperplasia: a systematic review and meta-analysis. Sexual Medicine Reviews. 2026;14(2):qeag029. doi:10.1093/sxmrev/qeag029
- Corona G, et al. Impact of combination therapy 5-alpha reductase inhibitors plus alpha-blockers on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. The Aging Male. 2017;20(1):13–22. doi:10.1080/13685538.2016.1195361
- Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. The Journal of Sexual Medicine. 2012;9(1):271–281. doi:10.1111/j.1743-6109.2011.02504.x
- Wang Y, Bao Y, Liu J, Duan L, Cui Y. Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction: a systematic review and meta-analysis. Lower Urinary Tract Symptoms. 2018;10(1):84–92. doi:10.1111/luts.12144
- Cui J, Cao D, Bai Y, et al. Efficacy and safety of 12-week monotherapy with once daily 5 mg tadalafil for lower urinary tract symptoms of benign prostatic hyperplasia: evidence-based analysis. Frontiers in Medicine. 2021;8:744012. doi:10.3389/fmed.2021.744012
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.